ADC Therapeutics (ADCT) Other Working Capital Changes (2020 - 2026)

ADC Therapeutics (ADCT) has reported Other Working Capital Changes for 7 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

• Quarterly Other Working Capital Changes rose 12.39% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.3 million (down 693.44% YoY) and the FY2025 annual result came in at -$2.5 million, up 63.84% from the prior year.
• Other Working Capital Changes grew to $2.2 million in Q1 2026 per ADCT's latest filing, from -$8.8 million in the prior quarter.
• Over the last five years, Other Working Capital Changes for ADCT reached as high as $17.6 million in Q4 2022 and fell as low as -$4.3 million in Q2 2023.
• A 5-year average of -$93235.3 and a median of -$643000.0 in 2023 frame the typical range for Other Working Capital Changes.
• Annual changes were most pronounced in 2022 — Other Working Capital Changes surged 279.34% — and 2024, when it plunged 1559.94%.
• Year by year, Other Working Capital Changes stood at -$1.7 million in 2022, then surged by 189.83% to $1.5 million in 2023, then slumped by 456.97% to -$5.4 million in 2024, then plunged by 62.44% to -$8.8 million in 2025, then soared by 125.01% to $2.2 million in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered $2.2 million, -$8.8 million, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.